Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Pharmacia R&D Head Ando Leaves For Celltech; Will Still Work With Pfizer

  • News

Executive Summary

Pharmacia R&D President Goran Ando, MD, will move to the other side of a partnership between Pharmacia and Celltech for the Phase III rheumatoid arthritis agent CDP-870 as Celltech CEO

You may also be interested in...



UCB Acquiring Celltech; Phase III TNF Inhibitor At Center Of $2.7 Bil. Deal

UCB is paying $2.7 bil. to lock up rights to Celltech's TNF inhibitor CDP-870

UCB Acquiring Celltech; Phase III TNF Inhibitor At Center Of $2.7 Bil. Deal

UCB is paying $2.7 bil. to lock up rights to Celltech's TNF inhibitor CDP-870

Pharmacia Farms Out CEOs: Rothwell To Head Sanofi North America

Sanofi-Synthelabo North America CEO-designate Tim Rothwell will bring extensive experience in the low-molecular weight heparin category to help re-energize the launch of Arixtra

Table

View full table

Related Content

Pink Sheet
Tags:
Latest Headlines

Post-Brexit UK Risks Being ‘Left Out In The Cold’ As EU Coordinates Action On Shortages

Gene Therapy: Pediatric Development Could Start Sooner Than Sponsors Think – FDA OTP Director

Puberty Blockers: FDA's Califf Asked If REMS, Boxed Warning Against Off-Label Use In The Works

ADHD Drugs: FDA Commissioner Blames Inappropriate Prescribing For Shortages

See All
UsernamePublicRestriction

Register

PS041664

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By